KCNJ5 gene somaticmutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism

Journal of Hypertension

Volumn 32, Issue 7, 2014, Pages 1514-1522

  Rossi, Gian Paolo ^a   Cesari, Maurizio ^a   Letizia, Claudio ^b   Seccia, Teresa M ^a   Cicala, Maria Verena ^b   Zinnamosca, Laura ^a   Kuppusamy, Maniselvan ^b   Mareso, Sara ^c   Sciomer, Susanna ^a   Iacobone, Maurizio ^a   Mantero, Franco ^a   Pessina, Achille C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Minimally Invasive Endocrine Surgery Unit Department of Surgery   (Italy)

Author keywords

Adrenal; Aldosteronism; Cardiac hypertrophy; Gene mutations; Potassium channel KCNJ5

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; POTASSIUM CHANNEL KIR 3.1; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; KCNJ5 PROTEIN, HUMAN;

ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; REMISSION; SOMATIC MUTATION; ADENOMA; ADRENAL CORTEX TUMOR; BIOSYNTHESIS; COMPLICATION; GENETICS; HEART VENTRICLE REMODELING; HYPERALDOSTERONISM; HYPERTROPHY, LEFT VENTRICULAR; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADENOMA; ADRENAL CORTEX NEOPLASMS; ADRENALECTOMY; ALDOSTERONE; FEMALE; FOLLOW-UP STUDIES; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MUTATION; VENTRICULAR REMODELING;

EID: 84903887123     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000186     Document Type: Article

References (34)

1. Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331:768-772
2. Oki K, Plonczynski MW, Luis Lam M, Gomez-Sanchez EP, Gomez- Sanchez CE. Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology 2012; 153:1774-1782
3. Boulkroun S, Beuschlein F, Rossi GP, Golib-Dzib JF, Fischer E, Amar L, et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012; 59:592-598
4. Azizan EA, Murthy M, Stowasser M, Gordon R, Kowalski B, Xu S, et al. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension 2012; 59:587-591
5. Taguchi R, Yamada M, Nakajima Y, Satoh T, Hashimoto K, Shibusawa N, et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. J Clin Endocrinol Metab 2012; 97:1311-1319
6. Charmandari E, Sertedaki A, Kino T, Merakou C, Hoffman DA, Hatch MM, et al. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab 2012; 97:E1532-E1539
7. Mulatero P, Tauber P, Zennaro MC, Monticone S, Lang K, Beuschlein F, et al. KCNJ5 mutations in European families with nonglucocorticoid remediablefamilialhyperaldosteronism.Hypertension2012;59:235-240
8. Scholl UI, Nelson-Williams C, Yue P, Grekin R, Wyatt RJ, Dillon MJ, et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A 2012; 109:2533-2538
9. Gomez-Sanchez CE, Oki K. Mini review: potassium channels and aldosterone dysregulation: is primary aldosteronism a potassium channelopathy? Endocrinology 2014; 155:47-55
10. Seccia TM, Mantero F, Letizia C, Kuppusamy M, Caroccia B, Barisa M, et al. Somatic mutations in the KCNJ5 gene raise the lateralization index: implications for the diagnosis of primary aldosteronism by adrenal vein sampling. J Clin Endocrinol Metab 2012; 97:E2307-E2313
11. Rossi GP, Bolognesi M, Rizzoni D, Seccia TM, Piva A, Porteri E, et al. Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 2008; 51:1366-1371
12. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008; 19:88-90
13. Reincke M, Fischer E, Gerum S, Merkle K, Schulz S, Pallauf A, et al. Observational study mortality in treated primary aldosteronism: the German Conn's registry. Hypertension 2012; 60:618-624
14. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension 2013; 62:331-336
15. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243-1248
16. Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension 2013; 62:62-69
17. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:3266-3281
18. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006; 48:232-238
19. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751-1762
20. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48:2293- 2300
21. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450- 458
22. Wallerson DC, Ganau A, Roman MJ, Devereux RB. Measurement of cardiac output by M-mode and two-dimensional echocardiography: application to patients with hypertension. Eur Heart J 1990; 11 (Suppl I): 67-78
23. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7:79-108
24. Muiesan ML, Salvetti M, Paini A, Monteduro C, Galbassini G, Bonzi B, et al. Inappropriate left ventricular mass changes during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2007; 49:1077-1083
25. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976; 37:7-11
26. Rossi GP. A comprehensive review of the clinical aspects of primary aldosteronism. Nat Rev Endocrinol 2011; 7:485-495
27. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, Laragh JH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105:173-178
28. Robert V, Van Thiem N, Cheav SL, Mouas C, Swynghedauw B, Delcayre C. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 1994; 24:30-36
29. Yamada M, Kushibiki M, Osanai T, Tomita H, Okumura K. Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization. Cardiovasc Res 2008; 79:169-178
30. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997; 95:1471-1478
31. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168:80-85
32. Pitt B, Ahmed A, Love TE, Krum H, Nicolau J, Cardoso JS, et al. History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure. Hypertension 2008; 52:271- 278
33. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717
34. Akerstrom T, Crona J, Delgado Verdugo A, Starker LF, Cupisti K, Willenberg HS, et al. Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS One 2012; 7: e41926.